A large new trial found that common blood thinners cut the risk of stroke, major bleeding, and death by 69 percent in atrial fibrillation patients who doctors once considered borderline cases.
Quick Take
- A trial called SINGLE-AF randomly assigned 1,803 atrial fibrillation patients to either a blood thinner or no blood thinner.
- Patients taking apixaban or rivaroxaban saw a 69 percent drop in stroke, major bleeding, or cardiovascular death over two years.
- Major bleeding rates stayed roughly the same between both groups, easing a common worry about blood thinners.
- The study focused on patients at “intermediate” stroke risk, a group doctors have long struggled to advise.
A Trial Aimed At Medicine’s Gray Zone
Atrial fibrillation, an irregular heartbeat, raises stroke risk because blood can pool and clot inside the heart. Doctors have long used blood thinners for high-risk patients. But a large slice of atrial fibrillation patients fall into a murkier middle category, where the stroke risk is real but modest, and guidelines have only weakly recommended treatment. The SINGLE-AF trial set out to test that gray zone directly with real, randomized evidence.
Researchers enrolled 1,803 patients across 18 centers in South Korea, all of whom scored a 1 on the standard stroke-risk scale for men, or a 2 for women. That score reflects roughly a 1 to 2 percent yearly stroke risk, not sky-high, but not negligible. Half the patients received a direct oral anticoagulant. The other half received no blood thinner at all, mirroring how many real-world doctors already handle these cases.
The Numbers Behind The Headline
Patients taking a blood thinner, either apixaban twice daily or rivaroxaban once daily, saw the combined rate of stroke, major bleeding, or cardiovascular death fall to just 0.5 percent. Patients with no blood thinner hit 1.5 percent. That gap produced the 69 percent relative risk reduction, with a result strong enough to rule out chance as the explanation.
Stroke prevention appears to be doing most of the heavy lifting. One trial summary reported ischemic stroke rates of 0.1 percent in the treated group versus 1.1 percent in the untreated group, a striking gap given how rare strokes were overall in this study population.
Why The Bleeding Numbers Matter Just As Much
Blood thinners carry a well-known tradeoff: they stop clots but raise bleeding risk. That tradeoff is exactly why doctors have hesitated to prescribe them broadly for lower-risk atrial fibrillation patients. SINGLE-AF found no meaningful difference in major bleeding, 0.3 percent on blood thinners versus 0.5 percent without, suggesting the benefit did not come at a steep safety cost.
Doctor Boyoung Joung, who presented the findings at the European Society of Cardiology Congress, said the trial gives doctors something they never had before for this exact patient group: real randomized proof, not just educated guesswork, that treatment helps without adding bleeding risk.
Direct oral anticoagulants cut the risk of serious clinical events by 69% in atrial fibrillation patients with an intermediate risk of stroke, according to the randomized SINGLE-AF trial. The benefit was driven mainly by fewer ischemic strokes, with no inchttps://t.co/xvFog8Imas
— Michael W. Deem (@Michael_W_Deem) September 27, 2026
The American College of Cardiology independently reported the same 69 percent figure and the same risk calculation, which matters because it shows the result was not an outlier reported by just one source. Two separate cardiology organizations reviewed the same data and reached the same conclusion at nearly the same time.
What This Means For Patients And Doctors
Current guidelines already suggest doctors “consider” blood thinners for this intermediate-risk group, but that soft language has left plenty of room for doctors to skip treatment, especially in patients worried about bleeding or the hassle of daily medication. This trial gives doctors and patients a much firmer number to weigh instead of a vague recommendation.
The trial was conducted entirely in South Korea, so doctors elsewhere may want to see the results confirmed in other countries before treating it as a global standard. Even so, the size of the benefit, paired with a neutral bleeding result, gives patients in this common but often overlooked risk category a much clearer case for starting treatment sooner rather than waiting.
Sources:
sciencedaily.com, acc.org, acdis.org, solaci.org, escardio.org
